The CFO is moving on. A classic red flag for companies, but let’s hope it’s just normal career advancement.
Knuutti has large stock options, doesn’t he believe in the company’s growth potential anymore? Where could he have gotten a better offer?
People’s lives can be affected by things other than money. For example, family matters.
Go ahead and submit a job application, there certainly seems to be no shortage of experts here.
It might even be good to shake things up a bit… And the chairman of the board could be shown the door at the same time
Kun luin tiedotteen aloin itkemään. Tuleekohan tästä kohta analyytikon kommentti?
Miksi tulisi? Saahan ihmiset vaihtaa työpaikkaa. Ne voi joskus tunteet mennä yli näin perjantai-iltana. Auringon noustessa tuntuu jo paremmalta.
Lumo featured this time at Eyenuk’s booth in Vancouver:
It looks like this collaboration is turning global, which explains why there’s quite a bit of mutual liking going on back and forth on LinkedIn. Now Eyenuk has also commented on the India post that was shared here earlier.
I don’t know if there’s some kind of domino effect going on, but as far as I understand, a CFO change on the Helsinki Stock Exchange is quite… normal? During 2026, there have already been 16 such changes, and Optomed’s makes it the 17th in line.
Edit. If this is causing people to cry about it, has the position become too big?
Great to see the long-standing Eyenuk partnership gaining momentum and visibility across multiple markets now. And a good boost for Lumo.
Sakke seems to have done a 7-year stint at Optomed. Most likely headhunted by a bigger firm, and the temptation was big enough. Hopefully, a talented successor will be found; the company is starting to be in good shape after the cost cuts .
Optomed and Eyenuk have been coming up more frequently on the forum lately. I wonder if Aimil in India has abandoned their own AI development and is moving forward with Eyenuk’s EyeArt together with the Lumo camera?
And what about the US? Is there an ongoing FDA process seeking approval for the Lumo EyeArt combination?
In the US market, would it then be Lumo Aeye and Lumo EyeArt in the future?? And later on, also Lumo AeyeX.
If a small mom-and-pop shop is right on the verge of a breakthrough—why would the CFO bail for a bigger company?
Quite a big red flag, and it admittedly stings that I jumped back into this again this week; cut 1/3 yesterday because of this news at about a 10% loss in a couple of days.
I’ve definitely taken losses on this company before.
I couldn’t find Lumo off the top of my head, but EyeArt and Auroa IQ are included here: ClinicalTrials.gov
The sponsor is indeed a university, and even AI couldn’t tell who benefits from this if it goes through.
In our company, the CFO left right on the verge of growth for the exact reason that they had joined a smaller firm and wanted to continue working in one going forward. They had experience with larger companies as well, and the only upside there is the perceived prestige from others. For one’s personal life and family, a role at a larger corporation is an overall negative, and you really have to wonder why anyone would want to do it.